Clinical Trials in Phoenix

Showing 1441-1460 of 7,960 trials

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT07187479

The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).

Chronic Kidney Disease (Stages 4 and 5)Kidney DiseaseType 2 Diabetes

Well Cell Global120 participantsStarted Oct 2025

Phoenix, Arizona, United States

Active Not RecruitingPhase 2< 1 mile

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

Diffuse Cutaneous Systemic SclerosisInterstitial Lung Disease

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)154 participantsStarted Mar 2022

Phoenix, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +92 more locations

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Find Trials by Condition in Phoenix

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Gilteritinib for the Treatment of ALK NSCLC

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

IN.PACT™ AV Access Post-Approval Study (PAS002)

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention